| Objective:To observe the clinical efficacy of Zhulingjianpi capsule in the treatment of diarrhea irritable bowel syndrome,to evaluate the improvement and safety of clinical symptoms such as abdominal pain,abdominal distension and so on,so as to popularize and apply it in the future.Methods:From December 2017 to November 2018,we selected 134 patients with irritable bowel syndrome(IBS)who met the Rome IV diagnostic criteria in Yan’an University affiliated Hospital.All patients were divided into observation group(n = 67)and control group(n = 67).The observation group was given Zhulingjianpi capsule orally,3 tablets per time,3 times a day for 4 weeks,and the control group was given bifidobacterium Lactobacillus triple live bacteria tablets,4 tablets per time,3 times a day for 4 weeks.The scores of symptom severity were recorded before and after treatment,and the safety indexes were recorded in the course of medication.The clinical efficacy and safety of Zhulingjianpi capsule in the treatment of IBS-D were compared and analyzed.The study data were treated with SPSS24.0,P<0.05,the difference was statistically significant;P>0.05,the difference was not statistically significant.Results:1.Before treatment,there was no significant difference in sex,age,weight and course of disease between the two groups(P > 0.05),but there was significant difference in height(P < 0.05).Because height had no effect on dosage,the two groups were comparable.2.Compared with the 0 week,the total score of symptom severity in the fourth week was significantly lower in the two groups,and there was a significant difference between the two groups(P < 0.01).Compared with the 0 week,the total score of symptom severity in the 12 th week was lower than that in the 0 week group,and there was a significant difference between the two groups(P < 0.01).3.Before treatment,there was no significant difference between the two groups in the overall score of symptom severity(P > 0.05),and there was comparability between the two groups.In the fourth week,the total score of symptom severity in the two groups was significantly decreased,and there was a significant difference between the two groups(P < 0.01).4.In the observation group,at week 4,compared with week 0,week 12 and week 0,the scores of five symptoms were significantly lower than those before treatment(P < 0.05),and the degree of abdominal pain was significantly lower than that before treatment(P < 0.05).The degree of satisfaction with defecation was highly statistically significant(P < 0.01).5.The scores of five symptoms in the control group at week 4 were significantly lower than those at week 0,and there was significant difference between the two groups(P < 0.05).At the 12 th week,the scores of abdominal distension,satisfaction with defecation and influence on life were lower than those at week 0,but there was no significant difference in self-matching(P > 0.05).6.At week 0,the five symptom severity scores of the two groups were not statistically significant(P>0.05),which was comparable.At the 4th week and the 12 th week,the two groups of patients had statistically significant differences in the degree of abdominal pain and life impact scores(P<0.05),and the scores of abdominal distension between the two groups were highly statistically significant(P < 0.01).At the 4th week,there was no statistically significant difference in the degree of defecation between the two groups(P>0.05).At the 12 th week,there was a statistically significant difference between the two groups(P<0.05).7.Clinical effect:In the fourth week,the total effective rate was 88.06% in the observation group and 79.10% in the control group.The curative effect of the two groups was highly statistically significant(Z =-2.911,P < 0.01).The curative effect of the observation group was better than that of the control group.At the 12 th week,the total effective rate was 77.61% in the observation group and 56.71% in the control group(P < 0.01).The curative effect in the observation group was better than that in the control group(Z =-3.457,P < 0.01).8.Recurrence rate: At week 12,59 patients in the observation group were effective,7 patients relapsed,53 patients in the control group were effective,and 15 patients relapsed.The symptoms of all relapsed patients were less than those before treatment.The recurrence rate of the two groups was statistically significant(X2=4.779,P<0.05).9.Safety: in the 4th week and 12 th week,no obvious adverse reactions or side effects were found in 134 patients.There was no significant abnormality in blood,urine,fecal test,ECG,liver and kidney function before and after treatment.Conclusion:1.Zulingjianpi capsule have curative effect on diarrhea irritable bowel syndrome.2.The curative effect of Zhulingjianpi capsule was significantly better than that of gold bifid triple viable bacteria tablet,which could obviously improve the clinical symptoms of IBS.3.There was no obvious adverse reaction in zhuling jianpi capsule. |
PDF Full Text Request